HAE - Haemonetics Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
112.11
+0.33 (+0.30%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close 111.78
Open 111.61
Bid 112.33 x 1000
Ask 112.37 x 1000
Day's Range 110.86 - 112.64
52 Week Range 80.24 - 117.56
Volume 373,346
Avg. Volume 511,148
Market Cap 5.741B
Beta (3Y Monthly) 0.51
PE Ratio (TTM) 107.80
EPS (TTM) 1.04
Earnings Date Aug 5, 2019 - Aug 9, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 112.57
Trade prices are not sourced from all markets
  • Medical Products Industry Outlook: Growth Prospects Radiant
    Zacks 2 days ago

    Medical Products Industry Outlook: Growth Prospects Radiant

    Medical Products Industry Outlook: Growth Prospects Radiant

  • Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
    Zacks 3 days ago

    Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring

    Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.

  • Ecolab Unveils Innovative Tested Tool to Improve Food Safety
    Zacks 4 days ago

    Ecolab Unveils Innovative Tested Tool to Improve Food Safety

    Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.

  • Here's Why You Should Invest in Integer Holdings (ITGR) Stock
    Zacks 4 days ago

    Here's Why You Should Invest in Integer Holdings (ITGR) Stock

    Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

  • Here's Why You Should Retain HMS Holdings (HMSY) Stock
    Zacks 5 days ago

    Here's Why You Should Retain HMS Holdings (HMSY) Stock

    HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.

  • Markit 5 days ago

    See what the IHS Markit Score report has to say about Haemonetics Corp.

    Haemonetics Corp NYSE:HAEView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HAE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $194 million over the last one-month into ETFs that hold HAE are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
    Zacks 8 days ago

    Here's Why You Should Retain NextGen Healthcare (NXGN) Stock

    NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

  • Why Is Haemonetics (HAE) Up 7% Since Last Earnings Report?
    Zacks 9 days ago

    Why Is Haemonetics (HAE) Up 7% Since Last Earnings Report?

    Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Here's Why You Should Invest in DexCom (DXCM) Stock Now
    Zacks 9 days ago

    Here's Why You Should Invest in DexCom (DXCM) Stock Now

    DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.

  • Here's Why You Should Hold on to Medidata (MDSO) Stock Now
    Zacks 12 days ago

    Here's Why You Should Hold on to Medidata (MDSO) Stock Now

    Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.

  • 3 Reasons Growth Investors Will Love Haemonetics (HAE)
    Zacks 12 days ago

    3 Reasons Growth Investors Will Love Haemonetics (HAE)

    Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • A Note On Haemonetics Corporation's (NYSE:HAE) ROE and Debt To Equity
    Simply Wall St. 17 days ago

    A Note On Haemonetics Corporation's (NYSE:HAE) ROE and Debt To Equity

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
    Zacks 18 days ago

    Here's Why You Should Bet on Merit Medical (MMSI) Stock Now

    Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.

  • Here's Why You Should Consider Betting On CONMED Stock Now
    Zacks 19 days ago

    Here's Why You Should Consider Betting On CONMED Stock Now

    CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.

  • GuruFocus.com 24 days ago

    Haemonetics Corp (HAE) Files 10-K for the Fiscal Year Ended on March 31, 2019

    Haemonetics Corp (NYSE:HAE) files its latest 10-K with SEC for the fiscal year ended on March 31, 2019.

  • ABIOMED Gets FDA Confirmation of the Safety of Impella RP
    Zacks 24 days ago

    ABIOMED Gets FDA Confirmation of the Safety of Impella RP

    ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.

  • Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
    Zacks 25 days ago

    Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring

    Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.

  • 5 ‘Strong Buy’ Stocks Hedge Funds Are Buying Now
    TipRanks 25 days ago

    5 ‘Strong Buy’ Stocks Hedge Funds Are Buying Now

    Looking for fresh investing inspiration? Look no further. Hedge funds have just revealed their trades for the first quarter of 2019. This means we can see which stocks the ‘Smart Money’ is buying and selling right now. In this case, we used TipRanks algorithms to look at a large set of hedge funds and measure their exposure to each stock trading on the NASDAQ and NYSE. The following five stocks all score very highly on this basis. What’s more, all five stocks also boast the Street’s seal of approval with a ‘Strong Buy’ consensus based on all ratings received over the last three months. Interestingly, it appears that hedge funds are bullish on the market outlook despite fraught relationships between the US and China. “It would appear that the majority of hedge funds do not expect another sharp rise in volatility, and that they have concluded that the correction has run its course,” Nomura strategist Masanari Takada wrote.With this in mind let’s now take a closer look at five ‘Strong Buy’ hedge fund stock picks from 1Q19: Fiserv Inc (FISV – Research Report) Fiserv is a leading US provider of financial services technology. Year-to-date this is a stock that has performed strongly, with shares surging 19%. And according to analysts, the company is primed to continue outperforming. Indeed Fiserv has just announced a $22 billion acquisition of First Data Corp (FDC)- creating an impressive payments and fintech behemoth. The pending all-stock merger is expected to close in the second half of the year. First Data secures and processes more than 3,000 transactions per second and $2.4 trillion per year. Oppenheimer’s Glenn Greene is the 4 analyst on TipRanks out of over 5,000 tracked analysts. He is bullish on FISV stock, reiterating his buy rating after the deal was announced, and after Fiserv reported solid 1Q earnings results. “We remain attracted to FISV’s business model and long-term prospects and are highly enthusiastic about FISV’s pending merger with FDC, which should generate significant (>$1.4B) revenue/cost synergies, and related EPS accretion, over the next five years. Trading at 19x our FY20E pro forma EPS estimate including FDC, shares appear attractive” the analyst explained.View FISV Price Target & Analyst Ratings Detail Twilio Inc (TWLO – Research Report) Cloud communications platform Twilio also boasts notably positive hedge fund sentiment. Twilio allows software developers to programmatically make and receive phone calls, send and receive text messages, and perform other communication functions using its web service APIs.Luckily for hedge funds, shares have exploded by 54% year-to-date and 11% in the last five days alone. According to five-star Oppenheimer analyst Ittai Kidron, Twilio still has room to run given its ‘elongated high-growth trajectory.’ He has just carried out a deep-dive analysis of Twilio following the SendGrid merger, writing “our analysis yet again leaves us bullish and illustrates the upside left in the model, especially in 2H19/2020.”This is a company that benefits from the rapid adoption of application-to-person (A2P) communication; 2) a large and growing market as communication options expand (voice, SMS, video, etc.); and 3) a successful developer-focused sales model. “Overall, we believe these elements will enable Twilio to continue to experience strong revenue growth for the foreseeable future and drive upside to consensus expectations” concludes the analyst. View TWLO Price Target & Analyst Ratings Detail Sea Limited (SE – Research Report) If you haven’t head of Sea Limited before, this is a major Southeast Asia Internet company operating three popular online platforms. These focus on digital entertainment (Garena, gaming), eCommerce (Shopee, a third-party marketplace), and digital financial services (AirPay, e-wallet services). “Sea operates an established, profitable asset with its Garena segment that should help fund investments in its developing businesses (Shopee, AirPay) as they scale and gain market share” cheers Top 50 Stifel Nicolaus analyst Scott Devitt. He has a buy rating on SE with a $32 price target (24% upside potential).Devitt is confident going into the print later today, thanks to checks that indicate strong momentum for SE’s Free Fire video game. “While Free Fire’s user base is mobile-only and skews heavily to emerging markets, we continue to view the monetization potential as attractive” writes the analyst. Net-net: “With leverage to strong emerging growth markets and leading market positions, we recommend Sea as an investment idea.”He isn’t the only one. This is a stock with four back-to-back buy ratings from the Street:View SE Price Target & Analyst Ratings Detail Haemonetics Corp (HAE – Research Report) Haemonetics is a global provider of blood and plasma supplies. Its NexSys PC system is designed to enable organizations to collect more plasma with every donation. Shares are trading up 20% in the last month after a solid earnings beat in terms of profitability. What’s more, management provided strong financial guidance for FY/20, particularly in terms of non-GAAP EPS and cash flows.“We continue to view HAE as one of the best ideas in our coverage universe” enthuses Barrington Research’s Michael Petusky. He has just reiterated his HAE buy rating with a $116 price target (16% upside potential). “We continue to be very optimistic in terms of HAE’s key growth drivers (plasma and hospital) and remain quite bullish regarding the company’s ability to execute against its complexity reduction initiative goals. If the company was able to land any additional and sizable agreements connected to its NexSys PCS conversion activities, material additional upside to our estimates would be likely” explains Petusky. Meanwhile Raymond James’ Lawrence Keusch has just upgraded HAE from hold to buy, citing “a path towards 21% EPS growth over the next two years.”View HAE Price Target & Analyst Ratings Detail Regency Centers Corp (REG – Research Report) Last but not least comes Regency Centers. This Florida-based real estate investment trust (REIT) is one of the largest operators of grocery-anchored shopping centers. It is also one of RBC Capital’s favorite stock picks. “REG remains our top idea for retail despite noise from starting larger redevelopments” states the firm’s Wes Golladay. This top-ranked analyst recently reiterated his bullish call on REG with a $72 price target.“We believe Regency Centers remains well positioned for above-average long-term FFO/growth. The centers remain well leased, which should lead to optimal merchandising of centers and favorable pricing power on the organic front” writes the analyst. What’s more the company’s development platform should provide an additional layer of growth, and cash flow. That’s with a balance sheet that positions REG to be opportunistic should there be increased dislocation in retail real estate. “Regency has one of the best development platforms, in our opinion, which should lead to above-average development activity vs. the peer group” writes Golladay. View REG Price Target & Analyst Ratings Detail Find your own ‘Strong Buy’ stocksHere we covered hedge funds' top stock picks. Hedge fund sentiment is just one datapoint covered in the TipRanks' Smart Score. This new feature brings together all of TipRanks' unique insights- from hedge funds to insiders to bloggers- to give stocks a score out of 10. You can find 'Strong Buy' stocks with a 'perfect' score of 10 here.

  • Here's Why You Should Retain Cooper Companies (COO) Stock
    Zacks 26 days ago

    Here's Why You Should Retain Cooper Companies (COO) Stock

    Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.

  • 3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock
    Zacks 29 days ago

    3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock

    Haemonetics (HAE) could produce exceptional returns because of its solid growth attributes.

  • GuruFocus.com last month

    Haemonetics Corp (HAE) President & CEO Christopher Simon, Sold $5.4 million of Shares

    President & CEO of Haemonetics Corp (NYSE:HAE) Christopher Simon, sold 57,587 shares of HAE on 05/13/2019 at an average price of $94.51 a share.

  • Here's Why You Should Retain DaVita (DVA) in Your Portfolio
    Zacks last month

    Here's Why You Should Retain DaVita (DVA) in Your Portfolio

    DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

  • Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
    Zacks last month

    Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

    PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.